U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
Source link
Trending
- The latest rally may be only a dead-cat bounce, warns normally bullish boutique
- Assam CM Himanta Biswa Sarma meets ‘Team Europe’ delegation to boost trade, investment linkages
- Israel and Iran flare-up could strengthen Tehran’s negotiating hand
- ‘We want to see him in Ukraine’: Zelenskyy hopes to invite King Charles on state visit | King Charles III
- Bengaluru startup sets up Rs 3 crore semiconductor testing lab at IISc | India News
- Agniveer skill certificates may soon find their way to DigiLocker, will be linked with APAAR ID | Education News
- Alaskans Reel From the Loss of National Science Foundation Ocean-Monitoring Instruments
- Russia vs Trinidad and Tobago Prediction and Betting Tips
